Evidence map›Paper›PMID 33747914›Full record

SynthesisFrontiers in oncology2021

Prognostic Value of S100P Expression in Patients With Digestive System Cancers: A Meta-Analysis.

Bi-Xia Liu, Chao-Tao Tang, Xi-Jian Dai, Ling Zeng, Fei Cheng, Youxiang Chen, Chunyan Zeng

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Bi-Xia LiuDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Chao-Tao TangDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xi-Jian DaiDepartment of Psychiatry, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
Ling ZengDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Fei ChengDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Youxiang ChenDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Chunyan ZengDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Nanchang University · CNFirst Affiliated Hospital of Nanchang University · CNShenzhen KangNing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDigestive system cancers (DSCs) are associated with high morbidity and mortality. S100P has been reported as a prognostic biomarker in DSCs, but its prognostic value remains controversial. Accordingly, we conducted a meta-analysis to investigate whether S100P is correlated with overall survival (OS) of patients with DSCs. The relationship between S100P and clinicopathological features was also evaluated.

methodsWe systematically searched PubMed, Embase, Web of Science and Cochrane Library for eligible studies up to January 2020. In total, 16 publications with 1,925 patients were included.

resultsS100P overexpression was associated with poor OS of patient with DSCs (HR=1.54, 95% CI: 1.14-2.08, P=0.005). When stratified by anatomic structure, S100P overexpression was associated with poor prognosis in non-gastrointestinal tract cancers (HR=1.98, 95% CI: 1.44-2.72, P<0.001) but not in gastrointestinal tract cancers (HR=1.09, 95% CI: 0.66-1.81, P=0.727). When stratified by tumor type, S100P overexpression predicted poor OS in cholangiocarcinoma (HR=2.14, 95% CI: 1.30-3.50, P=0.003) and hepatocellular carcinoma (HR=1.91, 95% CI: 1.22-2.99, P =0.005) but not in gastric cancer (HR=0.97, 95% CI: 0.65-1.45, P=0.872), colorectal cancer (HR=1.18, 95% CI: 0.32-4.41, P=0.807), gallbladder cancer (HR=1.40, 95% CI: 0.84-2.34, P=0.198), and pancreatic cancer (HR=1.92, 95% CI: 0.99-3.72, P=0.053). Furthermore, high S100P expression was significantly associated with distant metastasis (OR=3.58, P=0.044), advanced clinical stage (OR=2.03, P=0.041) and recurrence (OR=1.66, P=0.007).

conclusionS100P might act as a prognostic indicator of non-gastrointestinal tract cancers.

Indexed as

cancersdigestive systemmeta-analysisprognosticS100 calcium-binding protein P (S100P)

Identifiers

PMID33747914
PMCPMC7973272
OpenAlexW3134804683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.